RVNC Annual FCF
-$223.46 M
-$26.70 M-13.57%
31 December 2023
Summary:
As of January 20, 2025, RVNC annual free cash flow is -$223.46 million, with the most recent change of -$26.70 million (-13.57%) on December 31, 2023. During the last 3 years, it has fallen by -$40.74 million (-22.30%). RVNC annual FCF is now -682.34% below its all-time high of -$28.56 million, reached on December 31, 2011.RVNC Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RVNC Quarterly FCF
-$41.15 M
-$3.02 M-7.91%
30 September 2024
Summary:
As of January 20, 2025, RVNC quarterly free cash flow is -$41.15 million, with the most recent change of -$3.02 million (-7.91%) on September 30, 2024. Over the past year, it has increased by +$14.31 million (+25.81%). RVNC quarterly FCF is now -502.77% below its all-time high of -$6.83 million, reached on September 30, 2013.RVNC Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RVNC TTM FCF
-$194.91 M
+$14.31 M+6.84%
30 September 2024
Summary:
As of January 20, 2025, RVNC TTM free cash flow is -$194.91 million, with the most recent change of +$14.31 million (+6.84%) on September 30, 2024. Over the past year, it has increased by +$15.51 million (+7.37%). RVNC TTM FCF is now -2721.51% below its all-time high of -$6.91 million, reached on March 31, 2013.RVNC TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RVNC Free Cash Flow Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -13.6% | +25.8% | +7.4% |
| 3 y3 years | -22.3% | +18.8% | +21.2% |
| 5 y5 years | +46.7% | -23.1% | -78.2% |
RVNC Free Cash Flow High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -13.6% | +3.6% | -30.8% | +42.1% | at high | +16.0% |
| 5 y | 5-year | -104.3% | +3.6% | -131.3% | +47.8% | -78.2% | +23.0% |
| alltime | all time | -682.3% | +46.7% | -502.8% | +87.9% | -2721.5% | +53.5% |
Revance Therapeutics Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$41.15 M(+7.9%) | -$194.91 M(-6.8%) |
| June 2024 | - | -$38.14 M(-46.4%) | -$209.22 M(-6.7%) |
| Mar 2024 | - | -$71.11 M(+59.8%) | -$224.20 M(+0.3%) |
| Dec 2023 | -$223.46 M(+13.6%) | -$44.51 M(-19.8%) | -$223.46 M(+6.2%) |
| Sept 2023 | - | -$55.47 M(+4.4%) | -$210.42 M(-1.6%) |
| June 2023 | - | -$53.12 M(-24.5%) | -$213.83 M(+4.6%) |
| Mar 2023 | - | -$70.37 M(+123.6%) | -$204.40 M(+3.9%) |
| Dec 2022 | -$196.76 M(-15.2%) | -$31.47 M(-46.5%) | -$196.76 M(-8.2%) |
| Sept 2022 | - | -$58.87 M(+34.8%) | -$214.26 M(+4.0%) |
| June 2022 | - | -$43.69 M(-30.3%) | -$206.05 M(-4.5%) |
| Mar 2022 | - | -$62.73 M(+28.1%) | -$215.85 M(-6.9%) |
| Dec 2021 | -$231.91 M(+26.9%) | -$48.97 M(-3.4%) | -$231.91 M(-6.3%) |
| Sept 2021 | - | -$50.67 M(-5.3%) | -$247.47 M(-2.3%) |
| June 2021 | - | -$53.48 M(-32.1%) | -$253.26 M(+16.4%) |
| Mar 2021 | - | -$78.79 M(+22.1%) | -$217.56 M(+19.1%) |
| Dec 2020 | -$182.72 M(+67.0%) | -$64.52 M(+14.3%) | -$182.72 M(+20.2%) |
| Sept 2020 | - | -$56.46 M(+217.4%) | -$151.99 M(+17.9%) |
| June 2020 | - | -$17.79 M(-59.5%) | -$128.96 M(-8.4%) |
| Mar 2020 | - | -$43.95 M(+30.0%) | -$140.84 M(+28.7%) |
| Dec 2019 | -$109.39 M(-73.9%) | -$33.80 M(+1.1%) | -$109.39 M(-73.7%) |
| Sept 2019 | - | -$33.43 M(+12.7%) | -$416.28 M(+1.2%) |
| June 2019 | - | -$29.66 M(+137.4%) | -$411.28 M(-2.0%) |
| Mar 2019 | - | -$12.50 M(-96.3%) | -$419.54 M(+0.1%) |
| Dec 2018 | -$419.26 M | -$340.69 M(+1098.1%) | -$419.26 M(+290.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2018 | - | -$28.44 M(-25.0%) | -$107.46 M(+6.4%) |
| June 2018 | - | -$37.92 M(+210.5%) | -$101.01 M(+13.9%) |
| Mar 2018 | - | -$12.21 M(-57.7%) | -$88.69 M(-9.5%) |
| Dec 2017 | -$97.97 M(+54.8%) | -$28.88 M(+31.3%) | -$97.97 M(+17.9%) |
| Sept 2017 | - | -$21.99 M(-14.1%) | -$83.07 M(+9.9%) |
| June 2017 | - | -$25.60 M(+19.1%) | -$75.58 M(+10.5%) |
| Mar 2017 | - | -$21.49 M(+53.6%) | -$68.42 M(+8.1%) |
| Dec 2016 | -$63.30 M(+7.3%) | -$13.99 M(-3.6%) | -$63.30 M(-4.4%) |
| Sept 2016 | - | -$14.51 M(-21.3%) | -$66.24 M(+0.4%) |
| June 2016 | - | -$18.43 M(+12.6%) | -$66.00 M(+9.0%) |
| Mar 2016 | - | -$16.37 M(-3.3%) | -$60.54 M(+2.6%) |
| Dec 2015 | -$59.00 M(-4.9%) | -$16.93 M(+18.7%) | -$59.00 M(+11.9%) |
| Sept 2015 | - | -$14.26 M(+9.9%) | -$52.72 M(-0.9%) |
| June 2015 | - | -$12.98 M(-12.5%) | -$53.17 M(-2.9%) |
| Mar 2015 | - | -$14.83 M(+39.2%) | -$54.78 M(-11.7%) |
| Dec 2014 | -$62.05 M(+14.4%) | -$10.65 M(-27.6%) | -$62.05 M(-10.3%) |
| Sept 2014 | - | -$14.72 M(+0.9%) | -$69.18 M(+12.9%) |
| June 2014 | - | -$14.59 M(-34.0%) | -$61.29 M(-11.7%) |
| Mar 2014 | - | -$22.09 M(+24.2%) | -$69.42 M(+28.0%) |
| Dec 2013 | -$54.23 M(+38.2%) | -$17.78 M(+160.5%) | -$54.23 M(+48.8%) |
| Sept 2013 | - | -$6.83 M(-69.9%) | -$36.45 M(+23.0%) |
| June 2013 | - | -$22.72 M(+228.8%) | -$29.62 M(+328.8%) |
| Mar 2013 | - | -$6.91 M | -$6.91 M |
| Dec 2012 | -$39.23 M(+37.4%) | - | - |
| Dec 2011 | -$28.56 M | - | - |
FAQ
- What is Revance Therapeutics annual free cash flow?
- What is the all time high annual FCF for Revance Therapeutics?
- What is Revance Therapeutics annual FCF year-on-year change?
- What is Revance Therapeutics quarterly free cash flow?
- What is the all time high quarterly FCF for Revance Therapeutics?
- What is Revance Therapeutics quarterly FCF year-on-year change?
- What is Revance Therapeutics TTM free cash flow?
- What is the all time high TTM FCF for Revance Therapeutics?
- What is Revance Therapeutics TTM FCF year-on-year change?
What is Revance Therapeutics annual free cash flow?
The current annual FCF of RVNC is -$223.46 M
What is the all time high annual FCF for Revance Therapeutics?
Revance Therapeutics all-time high annual free cash flow is -$28.56 M
What is Revance Therapeutics annual FCF year-on-year change?
Over the past year, RVNC annual free cash flow has changed by -$26.70 M (-13.57%)
What is Revance Therapeutics quarterly free cash flow?
The current quarterly FCF of RVNC is -$41.15 M
What is the all time high quarterly FCF for Revance Therapeutics?
Revance Therapeutics all-time high quarterly free cash flow is -$6.83 M
What is Revance Therapeutics quarterly FCF year-on-year change?
Over the past year, RVNC quarterly free cash flow has changed by +$14.31 M (+25.81%)
What is Revance Therapeutics TTM free cash flow?
The current TTM FCF of RVNC is -$194.91 M
What is the all time high TTM FCF for Revance Therapeutics?
Revance Therapeutics all-time high TTM free cash flow is -$6.91 M
What is Revance Therapeutics TTM FCF year-on-year change?
Over the past year, RVNC TTM free cash flow has changed by +$15.51 M (+7.37%)